NCT02115542View on ClinicalTrials.gov

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 5, 2014

Primary Completion Date

December 10, 2018

Study Completion Date

September 20, 2021

Conditions
Cancer of the Bile Duct
Interventions
DRUG

Regorafenib

Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.

Trial Locations (3)

23298

VCU Massey Cancer Center, Richmond

27514

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT02115542 - Single Agent Regorafenib in Refractory Advanced Biliary Cancers | Biotech Hunter | Biotech Hunter